摘要
目的观察酪丝亮肽治疗手术不能切除的原发性肝癌的疗效和安全性、毒副作用以及生活质量改善情况。方法30例病人随机分为3组,每组10例,分别予酪丝亮肽高剂量(4mg/d)、中剂量(2mg/d)、低剂量(2μg/d)单药静脉滴注治疗,每30天为1个疗程,连续给药6个疗程,低剂量组作为对照组。结果中剂量组和(或)高剂量组患者6个月中位生存期较低剂量组明显延长(超过180dvs59.0d),无明显毒副作用,临床耐受性良好。结论酪丝亮肽治疗手术不能切除的原发性肝癌有一定的疗效,无明显毒副作用,耐受性良好。
[Objectives] To evaluate the efficacy of Tyroserleutide on unresectable primary liver cancer, and the toxic effect, side effect and the improvement of the living quality. [Method] 30 cases of unresectable primary liver cancer were randomly divided into 3 groups： the high-dose group （slow intravenous infusion of Tyroserleutide 4 rag/ day, 10 cases）, the medial-dose group （slow intravenous infusion of Tyroserleutide 2 rag/day, 10 cases） and the lowdose group （slow intravenous infusion of Tyroserleutide 2μg/day, 10 cases）, 30-day treatmen period as one cycle, each patient would received 6 cycles of treatmen with Tyroserleutide intermittently, the low-dose group is the control group. [Result] The medial-dose group and （or） the high-dose group have remarkably longer medial survival time in 6 months than the low-dose group （more than 180 days vs 59.0 days）, without obvious toxic effect and side effec4 Tyroserleutide is safe and tolerable in clinical use. [Conclusions] Tyroserleutide on unresectable primary liver cancer is effective and welltolerable, without obvious toxic effect and side effect.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2007年第3期357-359,共3页
China Journal of Modern Medicine
关键词
酪丝亮肽
原发性肝癌
tyroserleutide
primary liver cancer
